表紙
市場調查報告書

前列腺素E2受體EP4次單元 (前列腺素EP4受體,PTGER4):開發中產品分析

Prostaglandin E2 Receptor EP4 Subtype - Pipeline Review, H1 2020

出版商 Global Markets Direct 商品編碼 363568
出版日期 內容資訊 英文 66 Pages
訂單完成後即時交付
價格
前列腺素E2受體EP4次單元 (前列腺素EP4受體,PTGER4):開發中產品分析 Prostaglandin E2 Receptor EP4 Subtype - Pipeline Review, H1 2020
出版日期: 2020年05月30日內容資訊: 英文 66 Pages
簡介

本報告提供全球各國的前列腺素E2受體EP4次單元 (別名前列腺素EP4受體或PTGER4) 治療藥的開發中產品的開發情形相關分析,產品開發、上市的最新趨勢,及臨床實驗的各階段的產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊,為您概述為以下內容。

目錄

  • 簡介
    • 分析範圍
  • 前列腺素E2受體EP4次單元 (前列腺素EP4受體,PTGER4)的概要
  • 治療藥的開發情形
    • 臨床實驗的各階段
    • 各治療領域
    • 各症狀
  • 開發中產品的概要
    • 後期階段的產品
    • 初期階段的產品
  • 各企業開發中的治療藥
  • 各大學、研究機關開發中的治療藥
  • 治療藥的評估
    • 單劑治療藥/並用治療藥的情況
    • 各作用機制
    • 各投藥法
    • 各分子類型
  • 開發治療藥的企業
    • AskAt Inc.
    • Eisai
    • Eli Lilly and Company
    • aken Pharmaceutical Co., Ltd.
    • 小野藥品工業
  • 藥物簡介
    • AAT-008
      • 產品概要
      • 作用機制
      • 研究開發 (R&D)的發展情形
    • CR-6086
    • E-7046
    • ER-886046
    • grapiprant
    • KAG-308
    • ONO-4232
    • P-001
    • 發炎痛用EP4受體拮抗用小分子
    • 子宮內膜異位症用前列腺素EP2、EP4受體拮抗用小分子
  • 開發暫停的產品
  • 開發中止的產品
  • 值得注意的最新趨勢、新聞稿 (1件)
  • 附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC2425TDB

Summary:

According to the recently published report 'Prostaglandin E2 Receptor EP4 Subtype - Pipeline Review, H1 2020'; Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) pipeline Target constitutes close to 17 molecules. Out of which approximately 16 molecules are developed by companies and remaining by the universities/institutes.

Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) - Prostaglandin E2 receptor 4 (EP4) is a prostaglandin receptor encoded by the PTGER4 gene. The activity of the receptor is mediated by G proteins that stimulate adenylate cyclase. It has a relaxing effect on smooth muscle. It plays an important role in regulating renal hemodynamics, intestinal epithelial transport, adrenal aldosterone secretion, and uterine function.

The report 'Prostaglandin E2 Receptor EP4 Subtype - Pipeline Review, H1 2020' outlays comprehensive information on the Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 5, 2, 7 and 2 respectively. Similarly, the universities portfolio in Discovery stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology, Musculoskeletal Disorders, Central Nervous System, Immunology, Gastrointestinal, Respiratory, Women's Health and Genetic Disorders which include indications Colorectal Cancer, Gastric Cancer, Triple-Negative Breast Cancer (TNBC), Autoimmune Disorders, Endometriosis, Head And Neck Cancer Squamous Cell Carcinoma, Lung Cancer, Metastatic Colorectal Cancer, Non-Small Cell Lung Cancer, Pain, Rectal Cancer, Allergies, Asthma, Bladder Cancer, Bone Defects, Breast Cancer, Chronic Obstructive Pulmonary Disease (COPD), Colon Cancer, Esophageal Cancer, Head And Neck Cancer, Hepatocellular Carcinoma, Inflammatory Bowel Disease, Inflammatory Pain, Knee Osteoarthritis, Liver Cancer, Lung Adenocarcinoma, Melanoma, Metastatic Pancreatic Cancer, Muscle Invasive Bladder Cancer (MIBC), Osteoarthritis, Osteoarthritis Pain, Osteogenesis Imperfecta, Osteoporosis, Prostate Cancer, Renal Cell Carcinoma, Rheumatoid Arthritis, Solid Tumor, Transitional Cell Cancer (Urothelial Cell Cancer) and Ulcerative Colitis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4)
  • The report reviews Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) targeted therapeutics

Reasons to Buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) - Overview
    • Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) - Therapeutics Development
    • Products under Development by Stage of Development
    • Products under Development by Therapy Area
    • Products under Development by Indication
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) - Therapeutics Assessment
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) - Companies Involved in Therapeutics Development
    • ARTham Therapeutics Inc
    • AskAt Inc
    • Eisai Co Ltd
    • GlaxoSmithKline Plc
    • Gurus BioPharm
    • Kaken Pharmaceutical Co Ltd
    • Mesentech Inc
    • NB Health Laboratory Co Ltd
    • Ono Pharmaceutical Co Ltd
    • RaQualia Pharma Inc
    • Rottapharm Biotech Srl
    • Shanghai Bioray Laboratory Inc
    • Sosei Heptares
    • Tempest Therapeutics Inc
    • Teon Therapeutics Inc
  • Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) - Drug Profiles
    • AAT-008 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ARTEP - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) - Dormant Products
  • Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) - Discontinued Products
  • Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H1 2020
  • Number of Products under Development by Therapy Areas, H1 2020
  • Number of Products under Development by Indications, H1 2020
  • Number of Products under Development by Indications, H1 2020 (Contd..1), H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..2), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..3), H1 2020
  • Number of Products under Investigation by Universities/Institutes, H1 2020
  • Products under Investigation by Universities/Institutes, H1 2020
  • Number of Products by Stage and Mechanism of Actions, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Pipeline by ARTham Therapeutics Inc, H1 2020
  • Pipeline by AskAt Inc, H1 2020
  • Pipeline by Eisai Co Ltd, H1 2020
  • Pipeline by GlaxoSmithKline Plc, H1 2020
  • Pipeline by Gurus BioPharm, H1 2020
  • Pipeline by Kaken Pharmaceutical Co Ltd, H1 2020
  • Pipeline by Mesentech Inc, H1 2020
  • Pipeline by NB Health Laboratory Co Ltd, H1 2020
  • Pipeline by Ono Pharmaceutical Co Ltd, H1 2020
  • Pipeline by RaQualia Pharma Inc, H1 2020
  • Pipeline by Rottapharm Biotech Srl, H1 2020
  • Pipeline by Shanghai Bioray Laboratory Inc, H1 2020
  • Pipeline by Sosei Heptares, H1 2020
  • Pipeline by Tempest Therapeutics Inc, H1 2020
  • Pipeline by Teon Therapeutics Inc, H1 2020
  • Dormant Projects, H1 2020
  • Discontinued Products, H1 2020
  • Discontinued Products, H1 2020 (Contd..1), H1 2020

List of Figures

  • Number of Products under Development by Stage of Development, H1 2020
  • Number of Products under Development by Therapy Areas, H1 2020
  • Number of Products under Development by Top 10 Indications, H1 2020
  • Number of Products by Mechanism of Actions, H1 2020
  • Number of Products by Stage and Mechanism of Actions, H1 2020
  • Number of Products by Routes of Administration, H1 2020
  • Number of Products by Stage and Routes of Administration, H1 2020
  • Number of Products by Molecule Types, H1 2020
  • Number of Products by Stage and Molecule Types, H1 2020